25.85
-0.02 (-0.08%)
| Penutupan Terdahulu | 25.87 |
| Buka | 25.87 |
| Jumlah Dagangan | 325,721 |
| Purata Dagangan (3B) | 982,247 |
| Modal Pasaran | 1,534,128,128 |
| Harga / Buku (P/B) | 3.37 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 13 Nov 2025 |
| EPS Cair (TTM) | -1.92 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 0.23% |
| Nisbah Semasa (MRQ) | 21.07 |
| Aliran Tunai Operasi (OCF TTM) | -73.96 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -45.43 M |
| Pulangan Atas Aset (ROA TTM) | -21.36% |
| Pulangan Atas Ekuiti (ROE TTM) | -31.30% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Enliven Therapeutics, Inc. | Bercampur | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 2.0 |
| Aktiviti Orang Dalam | -1.5 |
| Volatiliti Harga | -5.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | 4.0 |
| Purata | -0.10 |
|
Enliven Therapeutics Inc is a clinical-stage precision oncology company focused on the discovery and development of potentially first-in-class precision oncology therapies. Enliven’s programs are designed to address issues such as tolerability, combinability, resistance and disease escape through brain metastases. Its product candidates include ELVN-001 which is a potent, selective, small molecule kinase inhibitor designed to specifically target the BCR-ABL gene fusion, the oncogenic driver for patients with chronic myeloid leukemia, and the ELVN-002 which is central nervous system (CNS) penetrant and irreversible HER2 inhibitor with activity against wild type HER2 and various HER2 mutations. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| % Dimiliki oleh Orang Dalam | 4.75% |
| % Dimiliki oleh Institusi | 90.86% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Orbimed Advisors Llc | 30 Sep 2025 | 7,959,538 |
| Fairmount Funds Management Llc | 30 Sep 2025 | 3,711,444 |
| Vr Adviser, Llc | 30 Sep 2025 | 3,226,331 |
| Polar Capital Holdings Plc | 30 Sep 2025 | 3,095,007 |
| Novo Holdings A/S | 30 Sep 2025 | 1,426,260 |
| Vestal Point Capital, Lp | 30 Sep 2025 | 1,160,000 |
Tiada data dalam julat masa ini.
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| HEYMAN RICHARD A. | - | 27.05 | -1,230 | -33,272 |
| LYSSIKATOS JOSEPH P | - | 27.05 | -20,000 | -541,000 |
| Jumlah Keseluruhan Kuantiti Bersih | -21,230 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | -574,272 | |||
| Purata Pembelian Keseluruhan ($) | - | |||
| Purata Jualan Keseluruhan ($) | 27.05 | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| HEYMAN RICHARD A. | Pengarah | 20 Jan 2026 | Jual automatik (-) | 1,230 | 27.05 | 33,272 |
| LYSSIKATOS JOSEPH P | Pegawai | 20 Jan 2026 | Jual automatik (-) | 20,000 | 27.05 | 541,000 |
| Tarikh | Jenis | Butiran |
|---|---|---|
| 08 Jan 2026 | Pengumuman | Enliven Reports Positive Initial Phase 1b Data for ELVN-001 in CML and Outlines 2026 Clinical Milestones |
| 07 Jan 2026 | Pengumuman | Enliven Therapeutics Bolsters Board to Prepare for Next Phase of Development |
| 11 Dec 2025 | Pengumuman | Enliven Therapeutics Reports Inducement Grants as Permitted by the Nasdaq Listing Rules |
| 11 Dec 2025 | Pengumuman | Enliven Therapeutics Announces New CEO to Drive Next Phase of Development |
| 12 Nov 2025 | Pengumuman | /C O R R E C T I O N -- Enliven Therapeutics, Inc./ |
| 03 Nov 2025 | Pengumuman | Enliven Therapeutics Announces Clinical Data in CML Patients with Atypical Fusion Transcripts at ASH 2025 Annual Meeting |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |